Eli Lilly announces SURMOUNT-5 trial on Zepbound met primary endpoint

Eli Lilly (LLY) and Company announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound, a dual GIP and GLP-1 receptor agonist, compared to Wegovy, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to Wegovy across the trial. For the primary endpoint, participants treated with Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy at 72 weeks using the treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using Zepbound lost an average of 50.3 lbs and participants on Wegovy lost an average of 33.1 lbs. In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy. Additionally, participants treated with Zepbound achieved a superior average waist circumference reduction of 7.2 in, while those treated with Wegovy saw an average reduction of 5.1 in